REPLReplimune Group, Inc.
$13.03+178% 1Y
$13.03
$1.7052 weeks$15.97
REPL in its own filings
Nothing in REPL's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
184
Events found in the filings · across 650 filings · the record starts in 2018
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 16, 2026
Most recent filing · Form 8-K
- Record starts
- Jun 8, 2018
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- SEC comment-letter activity23 occurrences
- 2025-06-02
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 16, 2026On September 15, 2026, Replimune Group, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the three proposals, each of which is described in greater detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange …Charter/bylaw amendment or fiscal-year change · Form 8-K
- Aug 14, 2026Reports Fiscal First Quarter 2027 Financial Results and Provides.Earnings release · press release
- Aug 11, 2026On August 9, 2026, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald & Co. (each, an “Underwriter” and, collectively, the “Underwriters”), relating to the issuance and sale of an aggregate of 9,701,490 shares …Other event · Form 8-K/A
- Aug 10, 2026On August 9, 2026, Replimune Group, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald & Co. (“Cantor”) (each, an “Underwriter” and, collectively, the “Underwriters”), relating to the issuance and sale …Other event · Form 8-K
- Aug 7, 2026On August 6, 2026, Replimune Group, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has granted accelerated approval for TUDRIQEV TM (vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab for the treatment of adults with …Other event · Form 8-K
- Jul 31, 2026On July 30, 2026, Replimune Group, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee (the “Advisory Committee”) met to discuss the Company’s Biologics License Application (“BLA”) resubmission for RP1 (vusolimogene …Other event · Form 8-K
- Jul 30, 2026Vusolimogene oderparepvec-wtpg (TUDRIQEV )Regulation FD disclosure · press release
- Jun 29, 2026Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Jun 26, 2026Replimune Announces FDA Acceptance of RP1 Biologics.Regulation FD disclosure · press release
- May 29, 2026Replimune Announces Planned RP1 BLA Resubmission Following Productive.Regulation FD disclosure · press release
- Apr 13, 2026On April 10, 2026, the Company received a second Complete Response Letter from the FDA regarding the Company’s BLA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.Regulation FD disclosure · Form 8-K
- Feb 3, 2026On January 29, 2026 (the “Third Amendment Closing Date”), Replimune Group, Inc. (the “Company”) and certain subsidiaries of the Company (collectively, the “Borrowers”) entered into a Third Amendment to Loan and Security Agreement (the “Amendment”) with Hercules Capital, Inc. (“Hercules”), in its capacity as …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…